Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL1738

DEXRAZOXANE
💊 Approved Drug
Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
💊 Approved Drug
C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1

Basic Information

ChEMBL ID CHEMBL1738
Name DEXRAZOXANE
Phase Approved
Structure Type MOL
InChI Key BMKDZUISNHGIBY-ZETCQYMHSA-N
Therapeutic ✓ Yes

Known Names

ADR-529 Cardioxane Dexrazoxane Dexrazoxano ICRF-187 NSC-169780 Razoxane (+)-form Razoxane, (s)- Razoxane, d-
3
Targets
4
Activities
2
Assay Types
9
PK Parameters
20
Publications
9
Known Names
15
Indications
2
Mechanisms

Molecular Properties

268.3
MW (Da)
-2.71
ALogP
6
HBA
2
HBD
98.8
PSA (Ų)
0.54
QED
0
Ro5 Violations
3
Rot. Bonds

Drug Information

Molecule Type Small molecule
First Approval 1995
Availability Prescription
Chirality Single Enantiomer

Routes of Administration

Parenteral

Flags

Natural Product
USAN Stem -oxane
USAN Year 1990

Extended Properties

Molecular Formula C11H16N4O4
MW 268.27
Aromatic Rings 0
Heavy Atoms 19
NP-Likeness -0.48

Mechanism of Action

Mechanism Action Type Target Direct Efficacy
Iron sequestering agent SEQUESTERING AGENT Iron
DNA topoisomerase II inhibitor INHIBITOR DNA topoisomerase II

Indications

Hepatoblastoma Leukemia Lymphoma, Large B-Cell, Diffuse Precursor Cell Lymphoblastic Leukemia-Lymphoma Ganglioneuroblastoma Leukemia, Myeloid, Acute Multiple Sclerosis Myelodysplastic Syndromes Neuroblastoma Rhabdomyosarcoma Sarcoma Sarcoma, Ewing Heart Defects, Congenital Neoplasms Osteosarcoma

ATC Classification

V03AF02
dexrazoxane
Level 1: VARIOUS
Level 2: ALL OTHER THERAPEUTIC PRODUCTS

Activity Summary

IC50 3 meas. best 4.75
EC50 1 meas.

Target Activity Profile

Target Type Best pChEMBL Mean pChEMBL Best (nM) # Data
HL-60
CHEMBL383
IC50 4.75 4.75 18000.0 1
DNA topoisomerase 2-alpha
CHEMBL1806
IC50 4.4 4.4 40000.0 1
DNA topoisomerase 2-beta
CHEMBL3396
IC50 4.3 4.3 50000.0 1

Pharmacokinetic Data

Parameter Value Units Species
AUC 2711.0 ng.hr.mL-1 Canis lupus familiaris
AUC 5573.0 ng.hr.mL-1 Canis lupus familiaris
CL 3.1 mL.min-1.kg-1 Homo sapiens
CL 3.1 mL.min-1.kg-1 Homo sapiens
Fu 1.0 - Homo sapiens
MRT 3.0 hr Homo sapiens
T1/2 2.5 hr Homo sapiens
T1/2 1.8 hr Canis lupus familiaris
T1/2 1.2 hr Canis lupus familiaris

Activity Data Samples

Top measurements by pChEMBL value

Literature References

PubMed DOI Target Context # Activities
16472241 10.2174/1570163043334794 Hepatotoxicity 18
22194678 10.1371/journal.pcbi.1002310 Hepatotoxicity 14
15646539 10.1016/s0399-8320(04)95062-2 Unchecked 11
15646539 10.1016/s0399-8320(04)95062-2 NON-PROTEIN TARGET 8
18426954 10.1124/dmd.108.020479 ADMET 4
20014752 10.1021/tx900326k Hepatotoxicity 3
37468498 10.1038/s41467-023-40064-9 Thromboxane A2 receptor 2
19445515 10.1021/jm900403j Homo sapiens 2
37468498 10.1038/s41467-023-40064-9 Prostaglandin G/H synthase 1 2
- 10.6019/CHEMBL4808148 Histone deacetylase 6 2
- 10.6019/CHEMBL4651402 SARS-CoV-2 2
- 10.6019/CHEMBL4495565 SARS-CoV-2 2
37468498 10.1038/s41467-023-40064-9 Muscarinic acetylcholine receptor M1 2
26948801 10.1016/j.drudis.2016.02.015 Homo sapiens 2
28040393 10.1016/j.bmcl.2016.12.040 DNA topoisomerase 2-alpha 2
28068603 10.1016/j.ejmech.2017.01.003 HCT-15 2
37468498 10.1038/s41467-023-40064-9 Alpha-1A adrenergic receptor 2
- 10.1101/2020.04.03.023846 SARS-CoV-2 1
- 10.1101/2020.04.21.054387 SARS-CoV-2 1
22122518 10.1021/jm201095h Plasmodium falciparum 1

Data from ChEMBL 36 via Core Engine